| 172.81 3.69 (2.18%) | 05-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 213.39 | 1-year : | 249.24 |
| Resists | First : | 182.69 | Second : | 213.39 |
| Pivot price | 169.1 |
|||
| Supports | First : | 165.27 | Second : | 154.5 |
| MAs | MA(5) : | 172  |
MA(20) : | 168.71 |
| MA(100) : | 188.79 |
MA(250) : | 189.15 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 58 |
D(3) : | 60 |
| RSI | RSI(14): 52.6 |
|||
| 52-week | High : | 247.05 | Low : | 134.64 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ IQV ] has closed below upper band by 38.3%. Bollinger Bands are 4.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 175.05 - 176.11 | 176.11 - 177.12 |
| Low: | 166.72 - 167.95 | 167.95 - 169.13 |
| Close: | 170.91 - 172.74 | 172.74 - 174.49 |
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Mon, 18 May 2026
IQVIA (IQV) Fell Despite Strong Fundamentals - Yahoo Finance
Fri, 15 May 2026
Catholic Responsible Investments Equity Index Fund's IQVIA Holdings Inc(IQV) Holding History - GuruFocus
Fri, 15 May 2026
Is There Now An Opportunity In IQVIA Holdings Inc. (NYSE:IQV)? - Moomoo
Fri, 15 May 2026
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BeOne Medicines (ONC) and Nektar Therapeutics (NKTR) - The Globe and Mail
Wed, 13 May 2026
AI-powered trials to speed global biosimilar drugs in IQVIA-Kexing pact - Stock Titan
Wed, 13 May 2026
Assessing IQVIA Holdings (IQV) Valuation After Expanded AI Clinical Trial Collaboration With Kexing Biopharm - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 167 (M) |
| Shares Float | 159 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 102.4 (%) |
| Shares Short | 4,960 (K) |
| Shares Short P.Month | 4,510 (K) |
| EPS | 8.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 38.34 |
| Profit Margin | 8.3 % |
| Operating Margin | 13.6 % |
| Return on Assets (ttm) | 5.1 % |
| Return on Equity (ttm) | 22.4 % |
| Qtrly Rev. Growth | 8.3 % |
| Gross Profit (p.s.) | 32.89 |
| Sales Per Share | 99.64 |
| EBITDA (p.s.) | 17.97 |
| Qtrly Earnings Growth | 15 % |
| Operating Cash Flow | 2,700 (M) |
| Levered Free Cash Flow | 2,160 (M) |
| PE Ratio | 21.46 |
| PEG Ratio | 0.6 |
| Price to Book value | 4.5 |
| Price to Sales | 1.73 |
| Price to Cash Flow | 10.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|